Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

10.44
-0.4400-4.04%
Post-market: 10.550.1100+1.05%19:59 EDT
Volume:1.27M
Turnover:13.48M
Market Cap:798.85M
PE:-7.26
High:11.25
Open:11.02
Low:10.37
Close:10.88
52wk High:14.00
52wk Low:4.35
Shares:76.52M
Float Shares:60.06M
Volume Ratio:1.35
T/O Rate:2.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4390
EPS(LYR):-0.7210
ROE:-81.84%
ROA:-28.64%
PB:6.33
PE(LYR):-14.48

Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP)

TIPRANKS
·
Aug 14

BofA Adjusts Price Target on Candel Therapeutics to $12 From $9

MT Newswires Live
·
Aug 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS)

TIPRANKS
·
Aug 14

Candel Therapeutics Price Target Maintained with a $23.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 14

Candel Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Earnings Flash (CADL) Candel Therapeutics Posts Q2 Net Loss $0.52 a Share, vs. FactSet Est of $0.21 Loss

MT Newswires Live
·
Aug 13

Candel Therapeutics: Q2 EPS $-0.52

THOMSON REUTERS
·
Aug 13

Candel Therapeutics Q2 FY26 Net Loss Widens to $38.9 Million; R&D Expense More than Doubles to $19.8 Million

Reuters
·
Aug 13

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

THOMSON REUTERS
·
Aug 13

Candel Therapeutics Inc Expected to Post a Loss of 24 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Candel Therapeutics Grants Inducement Stock Options for 30,800 Shares at $10.01 Each

Reuters
·
Aug 04

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 04

Candel Therapeutics to Present Extended Phase 3 Data on Aglatimagene Besadenovec in Localized Prostate Cancer at ASTRO 2026

Reuters
·
Aug 03

Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston

GlobeNewswire
·
Jul 29

Candel Therapeutics Inc : Stifel Initiates Coverage with Buy Rating; Target Price $22

THOMSON REUTERS
·
Jul 13

Candel Therapeutics Initiated at Buy by Stifel

Dow Jones
·
Jul 13

Candel Therapeutics initiated with a Buy at Stifel

TIPRANKS
·
Jul 13

Candel Therapeutics Files Form 3 for Chief Commercial Officer Mark E. Sims

Reuters
·
Jul 09

Candel Therapeutics Grants New CCO Mark Sims Options for 285,000 Shares at $10.03 Each

Reuters
·
Jul 09

Candel Therapeutics Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 09